Smith+Nephew takes centre court sponsoring players competing at Wimbledon; global Sports Medicine technology leader helping athletes get back in the game
26 Juni 2024 - 9:00AM
Smith+Nephew takes centre court sponsoring players competing at
Wimbledon; global Sports Medicine technology leader helping
athletes get back in the game
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology
company, today announces it will sponsor tennis players
participating in The Championships, Wimbledon 2024 to spotlight its
advanced Sports Medicine portfolio alongside some of the greatest
athletes in the world. Smith+Nephew endeavours to help people live
their ‘Life Unlimited’ by aiding in their recovery from injury and
get them back to doing what they love.
Click to play video - Smith+Nephew Proud
Player Sponsor at The Championships, Wimbledon 2024
Tennis is an elegant sport but can be rough on the body –
especially to a player’s joints. Two common injuries1,2 that tennis
players suffer are rotator cuff tears in the shoulder and meniscus
tears in the knee. Smith+Nephew offers advanced solutions for both
of these injuries that are supported by clinical evidence and
time-tested results.
Smith+Nephew’s comprehensive Advanced Healing Solutions
portfolio is redefining biological healing in rotator cuff repair.
Backed by 10 years of clinical evidence and more than 100,000
procedures completed globally since its introduction in 2014, the
REGENETEN Bioinductive Implant has had a transformative impact,
offering a better solution for more than 1 million3 patients having
surgery for a rotator cuff tear each year. The collagen-based
implant supports the body’s natural healing response to facilitate
the formation of new tendon-like tissue to biologically augment the
existing tendon and change the course of rotator cuff tear
progression.4-10
Smith+Nephew also has an established track record of success in
knee repair including a 30-year legacy of saving the meniscus
rather than removing it. One of the most frequently published
meniscal repair devices on the market, the FAST-FIX◊ Family of
meniscal repair solutions has helped surgeons repair hundreds of
thousands11 of meniscal tears over the past 30 years due to its
ease of use,12 high fixation strength,*13-16 and strong, reliable
repairs.17-19 With an 88% mean success rate of all-inside
repairs,20 the FAST-FIX Family has truly helped patients return to
a Life Unlimited.
“Both Smith+Nephew and the players participating in Wimbledon
share a common thread as leaders in their respective fields and
being among the best at what they do,” said Christie Van Geffen,
Senior Vice President of Global Marketing for Sports Medicine at
Smith+Nephew. “It’s an honour to sponsor players competing in this
year’s Championship and we look forward to helping athletes all
over the world get back to performing at the highest level.”
If you would like to find out more about Smith+Nephew’s leading
Sports Medicine technology portfolio – including the REGENETEN
Bioinductive Implant and FAST-FIX Family of meniscal repair
solutions – please visit www.smith-nephew.com.
- ends –
Media Enquiries Dave Snyder
+1 (978)
749-1440 Smith+Nephew
david.snyder@smith-nephew.com
*As demonstrated in biomechanical testing
References
- Dines, JS et al. Tennis Injuries: Epidemiology,
Pathophysiology, and Treatment. J Am Acad Orth Surg.
2015;23(3):181-189
- Majewski M et al.Epidemiology of athletic knee injuries: A
10-year study. The Knee. 2006;13(3):184-188
- iData Research. Rotator cuff repair and reconstruction market
size, share and trends analysis (2023). Available at:
https://idataresearch.com/product/rotator-cuff-repair-reconstruction-market-size-share-and-trends-analysis-global-2023-2029-medsuite-includes-grafts-allografts-xenograft-synthetic-and-1-more/#.
Accessed December 19, 2023.
- Ruiz Ibán MA, Navlet MG, Marco SM, et al. Augmentation of a
transosseous equivalent repair in posterosuperior non-acute rotator
cuff tears with a bioinductive collagen implant decreases the
re-tear rate at one year. A randomised controlled trial.
Arthroscopy. Published online 12/27/2023.
- Bokor DJ, Sonnabend D, Deady L, et al. Evidence of healing of
partial-thickness rotator cuff tears following arthroscopic
augmentation with a collagen implant: a 2-year MRI follow-up.
Muscles, Ligaments Tendons J. 2016;6(1):16-25.
- Schlegel TF, Abrams JS, Bushnell BD, Brock JL, Ho CP.
Radiologic and clinical evaluation of a bioabsorbable collagen
implant to treat partial-thickness tears: a prospective multicenter
study. J Shoulder Elbow Surg. 2018 27(2):242-251.
- Van Kampen C, Arnoczky S, Parks P, et al. Tissue-engineered
augmentation of a rotator cuff tendon using a reconstituted
collagen scaffold: a histological evaluation in sheep. Muscles
Ligaments Tendons J. 2013;3(3):229-235.
- Arnoczky SP, Bishai SK, Schofield B, et al. Histologic
Evaluation of Biopsy Specimens Obtained After Rotator Cuff
Repair Augmented With a Highly Porous Collagen Implant.
Arthroscopy. 2017;33(2):278-283
- Bokor DJ, Sonnabend DH, Deady L, et al. Healing of
partial-thickness rotator cuff tears following arthroscopic
augmentation with a highly porous collagen implant: a 5-year
clinical and MRI follow-up. Muscles, Ligaments Tendons J.
2019;9(3):338-347.
- McElvany MD, McGoldrick E, Gee AO, Neradilek MB, Matsen FA,
3rd. Rotator cuff repair: published evidence on factors
associated with repair integrity and clinical outcome. Am J Sports
Med. 2015;43(2):491-500.
- Internal Smith+Nephew sales data from 2023 FY STGP RM
- Smith+Nephew 2015.Ver/Val, Protocol/Report, FAST-FIX 360
Delivery System. Internal Report. 15000994 Rev. E.
- Smith+Nephew 2004. Suture performance in standard arthroscopic
knots - Effects of material and design. Internal Report.
1061539 Rev. A.
- Smith+Nephew 2007. Internal Test Request - ULTRA FAST-FIX.
Internal Report. ITR-3457.
- Smith+Nephew 2010.The biomechanical performance of the FAST-FIX
360 meniscal repair system. Internal Report. DOF 10600596.
- Smith+Nephew 2007.Evaluation of the mechanical properties of
the ULTRA FAST-FIX meniscal repair system in a bovine meniscus
model. Internal Report. DOF 10600342
- Uzun E, Misir A, Kizkapan TB, et al. Evaluation of Midterm
Clinical and Radiographic Outcomes of Arthroscopically
Repaired Vertical Longitudinal and Bucket-Handle Lateral Meniscal
Tears. Orthop J Sports Med. 2019;7(5):1 - 8.
- Shearman A, Foster A, Wilson A, Risebury M, Yasen S. Excellent
medium-term survival of an all-inside tensionable knotted
suture device justifies repair of most meniscal tears encountered
during reconstructive knee ligament surgery. Knee Surg Sports
Traumatol Arthrosc. 2020:1-8.
- Laurendon L, Neri T, Farizon F, Philippot R. Prognostic factors
for all-inside meniscal repair. A 87-case series. OTSR.
2017;103(7):1017 - 1020.
- Johnson, D., Souter, P., Sedgwick, M.. Clinical Performance of
an All-inside Meniscal Repair Device: A Systematic Literature
Review with Meta-analysis. ISAKOS. 2023.
About Smith+Nephew
Smith+Nephew is a portfolio medical technology business focused
on the repair, regeneration and replacement of soft and hard
tissue. We exist to restore people’s bodies and their self-belief
by using technology to take the limits off living. We call this
purpose ‘Life Unlimited’. Our 18,000 employees deliver this mission
every day, making a difference to patients’ lives through the
excellence of our product portfolio, and the invention and
application of new technologies across our three global
business units of Orthopaedics, Sports Medicine & ENT and
Advanced Wound Management.
Founded in Hull, UK, in 1856, we now operate in more than 100
countries, and generated annual sales of $5.5 billion in 2023.
Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN).
The terms ‘Group’ and ‘Smith+Nephew’ are used to refer to Smith
& Nephew plc and its consolidated subsidiaries, unless the
context requires otherwise.
For more information about Smith+Nephew, please visit
www.smith-nephew.com and follow us on X, LinkedIn, Instagram
or Facebook.
Forward-looking Statements
This document may contain forward-looking statements that may or
may not prove accurate. For example, statements regarding expected
revenue growth and trading profit margins, market trends and our
product pipeline are forward-looking statements. Phrases such as
"aim", "plan", "intend", "anticipate", "well-placed", "believe",
"estimate", "expect", "target", "consider" and similar expressions
are generally intended to identify forward-looking statements.
Forward-looking statements involve known and unknown risks,
uncertainties and other important factors that could cause actual
results to differ materially from what is expressed or implied by
the statements. For Smith+Nephew, these factors include: conflicts
in Europe and the Middle East, economic and financial conditions in
the markets we serve, especially those affecting healthcare
providers, payers and customers; price levels for established and
innovative medical devices; developments in medical technology;
regulatory approvals, reimbursement decisions or other government
actions; product defects or recalls or other problems with quality
management systems or failure to comply with related regulations;
litigation relating to patent or other claims; legal and financial
compliance risks and related investigative, remedial or enforcement
actions; disruption to our supply chain or operations or those of
our suppliers; competition for qualified personnel; strategic
actions, including acquisitions and disposals, our success in
performing due diligence, valuing and integrating acquired
businesses; disruption that may result from transactions or other
changes we make in our business plans or organisation to adapt to
market developments; relationships with healthcare professionals;
reliance on information technology and cybersecurity; disruptions
due to natural disasters, weather and climate change related
events; changes in customer and other stakeholder sustainability
expectations; changes in taxation regulations; effects of foreign
exchange volatility; and numerous other matters that affect us or
our markets, including those of a political, economic, business,
competitive or reputational nature. Please refer to the documents
that Smith+Nephew has filed with the U.S. Securities and Exchange
Commission under the U.S. Securities Exchange Act of 1934, as
amended, including Smith+Nephew's most recent annual report on Form
20-F, which is available on the SEC’s website at www. sec.gov, for
a discussion of certain of these factors. Any forward-looking
statement is based on information available to Smith+Nephew as of
the date of the statement. All written or oral forward-looking
statements attributable to Smith+Nephew are qualified by this
caution. Smith+Nephew does not undertake any obligation to update
or revise any forward-looking statement to reflect any change in
circumstances or in Smith+Nephew's expectations.
◊ Trademark of Smith+Nephew. Certain marks registered in US
Patent and Trademark Office.
Smith and Nephew (TG:NPW1)
Historical Stock Chart
Von Dez 2024 bis Jan 2025
Smith and Nephew (TG:NPW1)
Historical Stock Chart
Von Jan 2024 bis Jan 2025